Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
3.150
+0.010 (0.32%)
At close: May 12, 2025, 4:00 PM
3.120
-0.030 (-0.95%)
After-hours: May 12, 2025, 7:00 PM EDT
Company Description
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 427 |
| CEO | Steven Basta |
Contact Details
Address: 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 United States | |
| Phone | 877 742 8466 |
| Website | phathompharma.com |
Stock Details
| Ticker Symbol | PHAT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001783183 |
| CUSIP Number | 71722W107 |
| ISIN Number | US71722W1071 |
| Employer ID | 82-4151574 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven L. Basta M.B.A. | Chief Executive Officer, President and Director |
| David A. Socks | Co-Founder and Director |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder and Chief Operating Officer |
| Molly Henderson CPA, MBA | Chief Financial and Business Officer |
| Jonathan Bentley | Senior Vice President and Head of Sales |
| Paul Cocja | Chief People Officer |
| Tom Harris | Chief Development Sciences Officer |
| Dr. Eckhard Leifke M.D., Ph.D. | Chief Medical Officer |
| Martin J. Gilligan | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 24, 2025 | SCHEDULE 13G/A | Filing |
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |